Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.

Trial Details

NCT ID

NCT05950139

Phase

PHASE1 / PHASE2

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

Peptide vaccine

Locations (sample)

Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

Histologically or cytologically confirmed diagnosis of stage IV NSCLC (or recurrent NSCLC not a candidate for definitive multimodality therapy)
Documented ALK rearrangement as detected by: (1) fluorescence in situ hybridization (FISH), (2) immuno-histochemistry (IHC), (3) tissue next-genera…
Ongoing treatment with crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib with at least stable disease ≥ 4 months
No known presence of the specific ALK acquired resistance alterations targeted by the study vaccine

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →